News & Trends - Pharmaceuticals

Can we guarantee supply of essential drugs in a global crisis?

Health Industry Hub | March 31, 2021 |
[Total: 1    Average: 5/5]

Pharma News: Australia may soon be able to produce essential drugs, including anaesthetics and treatments for antibiotic resistant superbugs, rapidly and entirely onshore, ending the need to import them.

A collaboration between Melbourne chemical company Boron Molecular and DMTC (formerly the Defence Materials Technology Centre) is testing a new system capable of synthesising drugs at scale, quickly and continuously.

“The system uses a method known as ‘flow chemistry’,” said Boron Molecular’s Director of Business Development, Dr Oliver Hutt. “It should give us the sovereign capability to produce life-saving drugs right here. We’ll be able to avoid supply chain delays from foreign manufacturers.”

The World Health Organisation publishes a list of medicines considered essential for public health and disease treatment. These include antibiotics, antivirals, plasma substitutes and treatments for a wide range of conditions such as migraine, tuberculosis, cancers and heart disease.

The new system means that Australia will have the capacity to produce many, even most, of them onshore. They include:

Digital & Innovation - Health Industry Hub Digital Series
  • Lidocaine, a local anaesthetic
  • Praziquantel, a critical treatment for parasitic worms 
  • Rifampicin, for treating leprosy
  • Linezolid, an essential treatment for the superbug methicillin-resistant staphylococcus aureus (MRSA), and drug-resistant tuberculosis.

“Australia doesn’t have the capacity to produce these domestically at short notice,” Dr Hutt said.

“That means we are subject to supply and cost issues on the other side of the world. This approach, if successful, means we can create the materials right here – making our medical system more flexible, more controllable and more resilient.”

Flow chemistry has been pioneered in Australia by the national science agency, CSIRO, and the CSIRO team is also supporting the DMTC project.

The method uses a precise balance of thermal and ingredient input controls that enable a chemical reaction to occur continuously. The process is often safer, more precise, and less expensive than traditional batch manufacturing.

DMTC Medical Countermeasures Program Leader, Dr Felicia Pradera, said the pilot program currently underway seeks to provide proof-of-concept that flow chemistry can be used to make large quantities of specific medications on demand.

“A ‘platform’ technology is one that validates a development pathway – once that process is proven with one therapeutic asset, the knowhow and expertise would be transferable to support Australia’s efforts to develop local manufacturing capability for other classes of pharmaceuticals,” Dr Pradera said.

Dr Pradera added that it was crucial to ensure that all medications produced by the system meet regulatory approvals.

“This important project contributes to the ongoing development of Australian capability in therapeutic manufacturing and to building secure, stable local supply chains,” Dr Pradera said. 

You may also like Will AbbVie’s life cycle extension strategies set Humira apart from the biosimilars?

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - The power of being an authentic leader

The power of being an authentic leader

Health Industry Hub | April 21, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]


Digital & Innovation

Healthcare Technology Digital Innovations - Data is the biggest challenge, and opportunity, for MedTech

Data is the biggest challenge, and opportunity, for MedTech

Health Industry Hub | April 21, 2021 |

Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]


News & Trends - Medical Technology

MedTech News - Thermo Fisher acquisition to better serve its pharma and biotech clients

Thermo Fisher acquisition to better serve its pharma and biotech clients

Health Industry Hub | April 21, 2021 |

MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]


News & Trends - Pharmaceuticals

Pharma News - First-in-class oncology drug candidate licensed by Aussie pharma

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]